scispace - formally typeset
S

Shahar Keinan

Researcher at Research Triangle Park

Publications -  55
Citations -  9956

Shahar Keinan is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Targeted drug delivery & Ruthenium. The author has an hindex of 24, co-authored 54 publications receiving 7414 citations. Previous affiliations of Shahar Keinan include Polaris Industries & University of North Carolina at Chapel Hill.

Papers
More filters
Journal ArticleDOI

Steering Electrons on Moving Pathways

TL;DR: In this paper, the influence of structural fluctuations on electron-transfer kinetics is amplified by the exponential decay of electron tunneling probabilities with distance, as well as the delicate interference among coupling pathways.
Journal ArticleDOI

Interfacial hydration, dynamics and electron transfer: multi-scale ET modeling of the transient [myoglobin, cytochrome b5] complex.

TL;DR: Interestingly, water plays a double role in this electron-transfer system, lowering the tunneling barrier as well as inducing protein interface remodeling that screens the repulsion between the negatively-charged propionates of the two hemes.
Journal ArticleDOI

Phospholipid-Based Prodrugs for Drug Targeting in Inflammatory Bowel Disease: Computational Optimization and In-Vitro Correlation.

TL;DR: The purpose of this work was to develop powerful modern computational approaches to allow optimized a-priori design of phospholipid (PL) based prodrugs for IBD drug targeting.
Journal ArticleDOI

The C5SiMe7+ cation: pyramidal, bicyclic, or cyclohexadienyl?

TL;DR: It is concluded that the C6Me7+ cation has the bicyclic structure but rapidly interconverts the ring positions to produce the very simple NMR spectra.
Journal ArticleDOI

Computational modeling and in-vitro/in-silico correlation of phospholipid-based prodrugs for targeted drug delivery in inflammatory bowel disease

TL;DR: This work presents a powerful in-silico modeling approach to guide the molecular design of novel prodrugs targeting the enzyme PLA2, which is overexpressed in the inflamed tissues of IBD patients.